外用人α1型基因工程干扰素治疗慢性宫颈炎673例疗效观察

Clinical observation of the effect of human α1 recombinant interferon in treatment of cevical erosion

1988年8月至1989年1月,本协作组使用长春生研所研制成功的二种不同剂量外用人α1型基因工程干扰素1×10~5IU/ml及1×10~6IU/ml治疗慢性宫颈炎673例,在一疗程后总有效率达84.3%及86.6%,较对照组卡那霉素及妇炎灵的66.3%及62.9%为高(P<0.005)。停药6个月后,干扰素治疗组总有效率上升至90.1%及95.7%,疗效仍高于卡那霉素组的69.5%(P<0.05)。对宫颈糜烂病例宫颈局部作拭子标本197份进行HPV—16DNA分子杂交,阳性率达41.6%,其中经干扰素治疗166例,其治疗前后的阳性率分别为41.6%及17.5%,说明干扰素对HPV—16有一定的抑制作用。推测它有可能是一种阻断宫颈癌发生的方法。

Two different doses of human recombinant interferon α 1 (Hu-rIFN-α 1) were applied locally in 673 patients with cervical erosion from Aug. 1988 to Jan. 1989. After one course of treatment the rate of total response in 337 cases treated with dose of 1×10~5 IU/ml and 336 cases with 1×10~6 IU/ml were 84.3%and 86.6%respectively. In comparison with those in kanamycin (66.3%)and Fuyanling (62.9%) the differences between them were very significant (P<0.005). Tne therapeutic effect persisted in 90.1%and 95.7% respectively at 6 months after termination of treatment. The rate of HPV-16 (+) from cervical erosion with DNA molecular hybridization was 41.6%and dropped to 17.5% after one course of treatment and therefore it was considered that the application of Hu-rIFN-α 1 to cervical erosion may be a method for prevention of cervical carcinoma.